Comparison 7. Efficacy at six months: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 ACR20	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Etanercept 10 mg SC twice weekly	1	423	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.84, 1.19]
1.2 Etanercept 25 mg SC twice weekly	3	814	Risk Ratio (M‐H, Random, 95% CI)	1.35 [0.97, 1.89]
2 ACR50	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Etanercept 10 mg SC twice weekly	1	423	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.76, 1.34]
2.2 Etanercept 25 mg SC twice weekly	3	814	Risk Ratio (M‐H, Random, 95% CI)	1.55 [1.02, 2.37]
3 ACR70	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Etanercept 10 mg SC twice weekly	1	423	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.59, 1.61]
3.2 Etanercept 25 mg SC twice weekly	3	814	Risk Ratio (M‐H, Random, 95% CI)	1.97 [1.09, 3.54]
4 Change in Total Sharp Score (from baseline)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Etanercept 10 mg SC twice weekly	1	425	Mean Difference (IV, Fixed, 95% CI)	‐0.25 [‐0.72, 0.22]
4.2 Etanercept 25 mg SC twice weekly	1	424	Mean Difference (IV, Fixed, 95% CI)	‐0.49 [‐0.92, ‐0.06]
5 Change in Erosion Score (from baseline)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 Etanercept 10 mg SC twice weekly	1	425	Mean Difference (IV, Fixed, 95% CI)	‐0.18 [‐0.49, 0.13]
5.2 Etanercept 25 mg SC twice weekly	1	424	Mean Difference (IV, Fixed, 95% CI)	‐0.38 [‐0.66, ‐0.10]
6 Change in Joint Space Narrowing Score (from baseline)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 Etanercept 10 mg SC twice weekly	1	425	Mean Difference (IV, Fixed, 95% CI)	‐0.07 [‐0.35, 0.21]
6.2 Etanercept 25 mg SC twice weekly	1	424	Mean Difference (IV, Fixed, 95% CI)	‐0.11 [‐0.35, 0.13]
7 DAS	2	177	Mean Difference (IV, Random, 95% CI)	‐0.76 [‐2.24, 0.71]
7.1 Etanercept 25 mg SC twice weekly	2	177	Mean Difference (IV, Random, 95% CI)	‐0.76 [‐2.24, 0.71]